Does Dr. Arundine study drug effects on the pancreas?

Yes, he studies how medications, particularly cancer treatments, can lead to conditions affecting the pancreas.

What specific conditions has Dr. Arundine researched?

He has researched drug-induced acute pancreatitis, especially in the context of cancer immunotherapy.

Is Dr. Arundine's work relevant for patients undergoing cancer treatment?

Yes, his work is particularly relevant for patients receiving immunotherapy, as it helps in understanding potential side effects that may arise.

Dario Arundine

Oncology Unit, "Antonio Cardarelli" Hospital, Naples, Italy.

4 publications 2021 – 2023 ORCID

Pancreatic Neoplasms Lung Neoplasms Acute Disease Pancreatitis Pancreas

What does Dario Arundine research?

Dario Arundine studies how certain medications, especially those used in cancer treatments, can affect the pancreas. One of his notable cases involved a 71-year-old man who developed acute pancreatitis, a serious inflammation of the pancreas, after receiving immunotherapy for lung cancer. Initially, scans appeared to indicate pancreatic cancer, but further investigation revealed that the actual problem was inflammation due to the medication. This kind of research is crucial because it helps doctors recognize potentially misleading symptoms in cancer patients, leading to timely and effective treatment strategies.

Key findings

In a specific case, a 71-year-old man's scans misdiagnosed drug-induced pancreatitis as pancreatic cancer, emphasizing the need for careful evaluation of symptoms.
Early recognition of drug-induced acute pancreatitis can lead to better treatment decisions, potentially improving patient outcomes.
Immunotherapy, while beneficial for treating cancer, can lead to complications such as pancreatitis, which requires awareness among healthcare providers.

Frequently asked questions

Does Dr. Arundine study drug effects on the pancreas?: Yes, he studies how medications, particularly cancer treatments, can lead to conditions affecting the pancreas.
What specific conditions has Dr. Arundine researched?: He has researched drug-induced acute pancreatitis, especially in the context of cancer immunotherapy.
Is Dr. Arundine's work relevant for patients undergoing cancer treatment?: Yes, his work is particularly relevant for patients receiving immunotherapy, as it helps in understanding potential side effects that may arise.

Publications in plain English

Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab.

2023

Cancer diagnosis & prognosis

Romano FJ, Ronga R, Ambrosio F, Arundine D, Longo V +15 more

Plain English
This study looked at how the ratio of two types of white blood cells—neutrophils and lymphocytes—can help predict survival in patients with advanced lung cancer who were treated with a specific immunotherapy drug called pembrolizumab. They found that patients with a higher immune cell ratio (above 4.8) had an average survival of just 7.6 months, while those with lower ratios lived much longer, averaging 34.8 months. This information is important because it helps doctors identify which patients might respond poorly to treatment and need different approaches. Who this helps: This helps doctors and patients by guiding treatment decisions in advanced lung cancer cases.

PubMed

Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy.

2022

Frontiers in pharmacology

Vitale MG, Crispo A, Arundine D, Ronga R, Barbato C +7 more

Plain English
In this study, researchers looked at a product called PMA-zeolite to see if it could help reduce side effects from chemotherapy, especially nerve damage, in patients with colorectal cancer. They followed 104 patients for about 30 months after initially starting treatment, and although there were no major differences in overall survival rates between the PMA-zeolite group and the placebo group, some positive signs appeared at the 7-month mark; specifically, patients taking PMA-zeolite showed better outcomes in terms of survival and fewer cancer progression events. This matters because finding effective ways to support cancer patients during treatment could improve their quality of life and treatment success. Who this helps: This helps colorectal cancer patients undergoing chemotherapy.

PubMed

Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking Cancer.

2022

Tomography (Ann Arbor, Mich.)

Di Serafino M, Ronza R, D'Auria D, Fiorentino R, Arundine D +9 more

Plain English
This study examined a case where a 71-year-old man developed drug-induced acute pancreatitis (DIP) after receiving immunotherapy for lung cancer. Initially, scans showed signs that looked like pancreatic cancer, but later tests confirmed it was actually inflammation caused by the treatment, not a tumor. This finding is important because recognizing DIP quickly can lead to better treatment decisions and outcomes for patients. Who this helps: This helps patients undergoing immunotherapy and their doctors.

PubMed

Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study.

2021

Oncotarget

Romano FJ, Barbato C, Biglietto M, Di Lauro V, Arundine D +11 more

Plain English
This research focused on the effects of combining levofolinate with the chemotherapy drug 5-Fluorouracil (5FU) in patients with metastatic colorectal cancer (mCRC). The study found that using this combination can significantly extend the time patients live without their cancer worsening, reducing the risk of death by 25%. These results show that this treatment approach can improve outcomes for mCRC patients, regardless of specific genetic factors or previous surgeries. Who this helps: This helps patients with metastatic colorectal cancer.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.